What testosterone replacement therapy options and potential side effects should be considered for a 46-year-old man with erectile dysfunction and low morning testosterone?

Testosterone Replacement Therapy: Options and Side Effects

Testosterone Replacement Formulations

For a 46-year-old man with erectile dysfunction and low morning testosterone, transdermal testosterone gel (1.62%, ~40 mg daily) should be the first-line formulation because it provides stable day-to-day testosterone levels and carries a significantly lower risk of erythrocytosis (15.4%) compared to injectable testosterone (43.8%). 1

Available Formulations

Transdermal Testosterone Gel

• Apply once daily in the morning, targeting mid-normal testosterone levels (500-600 ng/dL) 1
• Annual cost approximately $2,135, but 71% of patients prefer it for convenience and ease of use 1
• Lower erythrocytosis risk compared to injectables 1
• Critical safety warning: Children and women must never touch application areas, as accidental exposure can cause early puberty in children and unwanted hair growth in women 1

Intramuscular Testosterone Injections

• Testosterone cypionate or enanthate 100-200 mg every 2 weeks, or 50-100 mg weekly 1
• Annual cost approximately $156, making it the most economical option 1
• Peak serum levels occur 2-5 days after injection, with return to baseline by days 10-14 1
• Higher erythrocytosis risk (43.8% of users) compared to transdermal preparations 1
• For monitoring, measure testosterone levels midway between injections (days 5-7), targeting 500-600 ng/dL 1

Alternative Long-Acting Injectable

• Testosterone undecanoate 750 mg initially, repeat at 4 weeks, then every 10 weeks 1
• Fewer yearly injections with more stable levels 1

Expected Benefits and Realistic Expectations

Sexual Function (Primary Benefit)

• Small but statistically significant improvement in sexual function and libido (standardized mean difference 0.35) 2, 1
• Improvements typically seen within 3-6 months 1
• At 12 months, discontinue testosterone if no improvement in sexual function occurs 2, 1

Minimal or No Benefits for:

• Physical functioning, energy, or vitality (effect size too small to be clinically meaningful) 2, 1
• Depressive symptoms (standardized mean difference -0.19, classified as "less-than-small") 1
• Cognition, memory, or thinking ability 2, 1
• Fatigue or low energy (standardized mean difference 0.17, clinically insignificant) 1

Metabolic Benefits

• Improvements in fasting glucose, insulin resistance, triglycerides, and HDL cholesterol 1
• Modest improvement in bone mineral density (3.2% increase at lumbar spine, 1.4% at femoral neck) 1

Critical Side Effects and Monitoring Requirements

Erythrocytosis (Most Important Risk)

Erythrocytosis is the most significant risk of testosterone therapy, particularly with injectable formulations, occurring in up to 44% of users. 1

Monitoring Protocol:

• Document baseline hematocrit/hemoglobin before starting therapy 1
• Hematocrit >54% is an absolute contraindication to initiating or continuing therapy 1
• Check hematocrit at 2-3 months, then every 3-6 months during the first year, then annually 1
• If hematocrit rises >54%, withhold testosterone immediately and consider therapeutic phlebotomy in high-risk patients 1

Management Algorithm by Hematocrit Level:

• 50-52%: Continue with closer monitoring, consider dose reduction if trending upward 1
• 52-54%: Reduce testosterone dose by 25-50%, consider switching from injectable to transdermal 1
• >54%: Withhold therapy immediately, consider therapeutic phlebotomy (remove 500 mL blood every 1-2 weeks until <52%) 1

Cardiovascular Safety

The 2023 TRAVERSE trial (5,246 men with pre-existing or high cardiovascular risk) showed no significant increase in major adverse cardiac events or stroke with transdermal testosterone gel compared to placebo over 21.7 months. 1

• Men with recent myocardial infarction or stroke should wait 3-6 months before starting therapy 1
• Fluid retention may worsen heart failure; use caution and target mid-range testosterone levels (350-600 ng/dL) in patients with cardiovascular disease 1

Prostate Monitoring

Baseline Assessment (Men ≥40 years):

• Measure PSA; levels >4.0 ng/mL require urologic evaluation and negative prostate biopsy before initiating therapy 1
• Perform digital rectal examination to detect nodules or induration 1

Ongoing Monitoring:

• Recheck PSA at 2-3 months, then every 3-6 months during year one, then annually 1
• Refer to urology if PSA rises >1.0 ng/mL within first 6 months or >0.4 ng/mL per year thereafter 1

Other Side Effects

• Fluid retention 1
• Benign prostatic hyperplasia symptoms 1
• Sleep apnea (relative contraindication if severe and untreated) 1
• Gynecomastia 1
• Acne or oily skin 1
• Testicular atrophy and infertility (testosterone suppresses spermatogenesis and causes prolonged azoospermia) 1

Absolute Contraindications

Never initiate testosterone therapy in men with:

• Active desire for fertility preservation (use gonadotropin therapy instead: hCG plus FSH) 1
• Active or treated male breast cancer 1
• Prostate cancer 1
• Hematocrit >54% 1
• Severe untreated obstructive sleep apnea 1

Pre-Treatment Requirements

Before starting testosterone, confirm:

1. Two separate morning (8-10 AM) total testosterone measurements <300 ng/dL 1
2. Measure LH and FSH to distinguish primary from secondary hypogonadism 1
3. Document baseline hematocrit/hemoglobin 1
4. Obtain PSA and perform digital rectal exam (men ≥40 years) 1
5. Explicitly confirm the patient does NOT desire fertility, as testosterone causes prolonged azoospermia 1

Monitoring Schedule

Initial Phase (First Year):

• 2-3 months: Measure testosterone (midway between injections for injectables), hematocrit, PSA 1
• Every 3-6 months: Repeat testosterone, hematocrit, PSA, digital rectal exam 1

Long-Term (After Year One):

• Annually: Testosterone level, hematocrit, PSA, digital rectal exam 1

Special Considerations for This Patient

For a 46-year-old with erectile dysfunction:

• Combine testosterone with PDE5 inhibitors (sildenafil, tadalafil) for optimal erectile dysfunction management 1
• A minimal level of testosterone is required for complete PDE5 inhibitor effect 1
• If obesity is present, attempt weight loss (5-10% reduction) through calorie restriction and exercise before initiating testosterone, as this can improve testosterone levels naturally 1

Cost Considerations:

• If cost is a concern, intramuscular testosterone ($156/year) is significantly more economical than transdermal gel ($2,135/year) 1
• However, the higher erythrocytosis risk with injectables may necessitate more frequent monitoring and potential formulation switching 1

Critical Pitfalls to Avoid

• Do not diagnose hypogonadism on a single testosterone measurement; require two morning values <300 ng/dL 1
• Do not start testosterone without measuring LH/FSH, as the distinction between primary and secondary hypogonadism guides therapy and fertility counseling 1
• Do not initiate therapy without confirming the patient does not desire fertility 1
• Do not continue testosterone when hematocrit exceeds 54%; this is an absolute indication to withhold therapy 1
• Do not expect meaningful improvements in energy, physical function, or mood—these benefits are minimal even with confirmed hypogonadism 2, 1
• Do not ignore mild erythrocytosis (hematocrit 50-52%) in patients with cardiovascular disease, as even modest elevations increase thrombotic risk 1